摘要
目的 对131I-CL3治疗的中晚期食管癌、结直肠癌患者联合应用IL - 2 ,探讨提高中晚期食管癌、结直肠癌放射免疫治疗效果的方法 .方法 中晚期食管癌、结直肠癌患者 2 8例 ,分为131I-CL3治疗组 13例 ,131I-CL3+IL - 2治疗组 15例 .131I-CL3治疗组瘤内注射131I -CL3 1110～ 1480MBq/3～ 4mg/次 ;131I-CL3 +IL - 2治疗组除行相同于131I-CL3治疗组治疗外 ,在瘤内注射131I-CL3前 2周及后 4周加肌注IL - 2 ,每天 2次 ,每次 10万单位 ,全程 6周 ,注射IL - 2总量为 840万单位 .结果 :131I -CL3治疗组有效率 46 .2 % ;1年和 2年生存率分别为15 .4%和 0 % ;T细胞亚群治疗前后变化无差异 (p>0 .0 5 ) .131I-CL3+IL - 2治疗组有效率 6 0 % ;1年和 2年生存率分别为 40 %和 13 .3 % ,明显高于131I-CL3治疗组 (p <0 .0 5 ) ;治疗后CD3+细胞、CD4 +细胞和CD4 +/CD8+较治疗前明显升高 (p <0 .0 5 ) .结论 联合应用IL - 2的131I -CL3放射免疫治疗 ,对延长患者生存时间 ,促进机体免疫应答 ,提高中晚期食管癌。
Objective Combining IL-2 with 131 I-CL3 to treat the sufferers with advanced phase of oesophagus and colorectum carcinoma,in order to discuss the method that how to improve the curative effect of the radioimunotherapy of advanced phase of oesophagus and colorectum carcinoma. Methods 28 cases suffering from advanced phase of oesophagus and colorectum cancinoma were divided into two groups: 131 I-CL3 treatment group,13 cases; 131 I-CL3+IL-2 treatment group,15 cases.The sufferers of 131 I -CL3 treatment group were treated with 1110-1480MBq/3～4mg once,injecting intratumously;The sufferers of 131 I-CL3+IL-2 treatment group were treated with 100000 units of IL-2 injection intramuscular,2 times per day,2 weeks before and 4 weeks after the same treatment of 131 I-CL3 treatment group,the total dosage was 8400000 units.Results 131 I-CL3 treatment group:the total efficiency rate was 46.2%,the 1 year and 2 years survival rate was 15.4% and 0%,respectively T cell sub-group was not significant difference between pre-and post treatment(p>0.05); 131 I-CL3+IL-2 treatment group: the total efficiency rate was 60%,the 1 year and 2 years survival rate was 40% and 13.3%respectively,the survival rate in 131 I-CL3 treatment group was much higher than that in 131 I-CL3+IL-2 treatment group(p<0.05,p<0.01),CD 3 + cell、CD 4 + cell and CD 4 +/CD 8 + increased significantly after treatment(p<0.05). Conclusions The therapy of combining IL-2 with 131 I-CL3 is very beneficial to prolong the survival time of the sufferers,promoting the physical immunity response to the carcinoma,enhancing the physical effect of anti-cancer,and improving the curative effect of the radioimmunotherapy of the oesophagus and colorectum carcinoma.
出处
《现代临床医学生物工程学杂志》
2000年第3期202-204,共3页
Journal of Modern Clinical Medical Bioengineering
关键词
IL-2
食管癌
结直肠癌
放射免疫治疗
IL-2^(131) I-CL3 Oesophagus and colorectum carcinoma Radioimmunotherapy Curative effect
